At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Not Yet Opened 06-09 16:00:00 EDT
1.30
+0.03
+2.36%
盘后1.32
+0.02+1.54%
19:50 EDT
High1.33Low1.26Vol612.09K
Open1.29D1 Closing1.27Amplitude5.51%
Mkt Cap78.87MTradable Cap72.31MTotal Shares60.67M
T/O786.79KT/O Rate1.10%Tradable Shares55.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial
TIPRANKS  ·  06-04
MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial
MAIA Biotech doses 29 patients in Phase 3 THIO-104 lung cancer trial
Reuters  ·  06-04
MAIA Biotech doses 29 patients in Phase 3 THIO-104 lung cancer trial
Maia Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
THOMSON REUTERS  ·  06-04
Maia Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study
MT Newswires Live  ·  06-03
MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study
MAIA Biotechnology receives FDA clearance for amendment to IND application
TIPRANKS  ·  06-03
MAIA Biotechnology receives FDA clearance for amendment to IND application
Maia Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 Thio-101 Trial Expansion
THOMSON REUTERS  ·  06-03
Maia Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 Thio-101 Trial Expansion
MAIA Biotechnology announces open market purchases by CEO, director
TIPRANKS  ·  06-02
MAIA Biotechnology announces open market purchases by CEO, director
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)
TIPRANKS  ·  06-02
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)
MAIA says directors, officers hold 20.46% beneficial stake
Reuters  ·  06-02
MAIA says directors, officers hold 20.46% beneficial stake
Maia Biotechnology Announces Open Market Purchases by CEO and Director
THOMSON REUTERS  ·  06-02
Maia Biotechnology Announces Open Market Purchases by CEO and Director
Maia Biotechnology CEO Vlad Vitoc buys 72,700 common shares for $100,870.29
Reuters  ·  06-02
Maia Biotechnology CEO Vlad Vitoc buys 72,700 common shares for $100,870.29
Maia Biotechnology director Stan Smith acquires 75,000 shares valued at $100,200
Reuters  ·  06-02
Maia Biotechnology director Stan Smith acquires 75,000 shares valued at $100,200
Maia Bio CSO Sergei Gryaznov acquires 2,000 common shares worth $2,690
Reuters  ·  06-02
Maia Bio CSO Sergei Gryaznov acquires 2,000 common shares worth $2,690
Maia Biotech presents Phase 3 THIO-104 trial design for ateganosine in checkpoint-resistant lung cancer at ASCO 2026
Reuters  ·  06-01
Maia Biotech presents Phase 3 THIO-104 trial design for ateganosine in checkpoint-resistant lung cancer at ASCO 2026
Maia Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
THOMSON REUTERS  ·  06-01
Maia Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
GlobeNewswire  ·  06-01
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
MAIA Biotechnology Shareholders Back Board and Auditor Appointments
TIPRANKS  ·  05-22
MAIA Biotechnology Shareholders Back Board and Auditor Appointments
Maia Biotechnology shareholders ratify Grant Thornton as 2026 auditor
Reuters  ·  05-22
Maia Biotechnology shareholders ratify Grant Thornton as 2026 auditor
MAIA Biotechnology Ends ATM Stock Offering Agreement
TIPRANKS  ·  05-15
MAIA Biotechnology Ends ATM Stock Offering Agreement
Maia Biotechnology Inc - Sold 3.1 Mln Shares for Gross Proceeds of $5.7 Mln Under Sales Agreement - SEC Filing
THOMSON REUTERS  ·  05-15
Maia Biotechnology Inc - Sold 3.1 Mln Shares for Gross Proceeds of $5.7 Mln Under Sales Agreement - SEC Filing

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--